A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA.
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2012
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Serono S.A.
- 23 Nov 2012 New trial record